Selected research
Industry Research
Cell and Gene Therapy Enterprise Solutions Industry Research Report 2026
Market perspective
The global Cell and Gene Therapy Enterprise Solutions market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Cell and Gene Therapy Enterprise Solutions market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Cell and Gene Therapy Enterprise Solutions market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Cell and Gene Therapy Enterprise Solutions market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Cell and Gene Therapy Enterprise Solutions include Thermo Fisher Scientific, Miltenyi Biotec, Bruker Spatial Biology, Charles River Laboratories, Sartorius, Revvity, Red Cross Blood Services, Proteintech Group and Promega Corporation, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Cell and Gene Therapy Enterprise Solutions market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Cell and Gene Therapy Enterprise Solutions.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cell and Gene Therapy Enterprise Solutions Market by Company
Thermo Fisher Scientific
Miltenyi Biotec
Bruker Spatial Biology
Charles River Laboratories
Sartorius
Revvity
Red Cross Blood Services
Proteintech Group
Promega Corporation
BIOMÉRIEUX
QIAGEN
R&D Systems
Abcam
SGS
Azenta US
Vizient Inc
Cell and Gene Therapy Enterprise Solutions Segment by Type
Cell Therapy-Specific Solutions
Gene Therapy-Specific Solutions
Cell and Gene Therapy Enterprise Solutions Segment by Application
Academic/Research Lab
Biotech/Pharma Company
Clinical/Medical Institution
Cell and Gene Therapy Enterprise Solutions Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell and Gene Therapy Enterprise Solutions market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cell and Gene Therapy Enterprise Solutions and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell and Gene Therapy Enterprise Solutions.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Cell and Gene Therapy Enterprise Solutions companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cell Therapy-Specific Solutions
- Gene Therapy-Specific Solutions
Applications
- Academic/Research Lab
- Biotech/Pharma Company
- Clinical/Medical Institution
Companies covered
- Thermo Fisher Scientific
- Miltenyi Biotec
- Bruker Spatial Biology
- Charles River Laboratories
- Sartorius
- Revvity
- Red Cross Blood Services
- Proteintech Group
- Promega Corporation
- BIOMÉRIEUX
- QIAGEN
- R&D Systems
- Abcam
- SGS
- Azenta US
- Vizient Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Cell and Gene Therapy Enterprise Solutions by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cell Therapy-Specific Solutions
- 2.2.3 Gene Therapy-Specific Solutions
- 2.3 Cell and Gene Therapy Enterprise Solutions by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Academic/Research Lab
- 2.3.3 Biotech/Pharma Company
- 2.3.4 Clinical/Medical Institution
- 2.4 Assumptions and Limitations
3 Cell and Gene Therapy Enterprise Solutions Breakdown Data by Type
- 3.1 Global Cell and Gene Therapy Enterprise Solutions Historic Market Size by Type (2021-2026)
- 3.2 Global Cell and Gene Therapy Enterprise Solutions Forecasted Market Size by Type (2027-2032)
4 Cell and Gene Therapy Enterprise Solutions Breakdown Data by Application
- 4.1 Global Cell and Gene Therapy Enterprise Solutions Historic Market Size by Application (2021-2026)
- 4.2 Global Cell and Gene Therapy Enterprise Solutions Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Cell and Gene Therapy Enterprise Solutions Market Perspective (2021-2032)
- 5.2 Global Cell and Gene Therapy Enterprise Solutions Growth Trends by Region
- 5.2.1 Global Cell and Gene Therapy Enterprise Solutions Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Cell and Gene Therapy Enterprise Solutions Historic Market Size by Region (2021-2026)
- 5.2.3 Cell and Gene Therapy Enterprise Solutions Forecasted Market Size by Region (2027-2032)
- 5.3 Cell and Gene Therapy Enterprise Solutions Market Dynamics
- 5.3.1 Cell and Gene Therapy Enterprise Solutions Industry Trends
- 5.3.2 Cell and Gene Therapy Enterprise Solutions Market Drivers
- 5.3.3 Cell and Gene Therapy Enterprise Solutions Market Challenges
- 5.3.4 Cell and Gene Therapy Enterprise Solutions Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Cell and Gene Therapy Enterprise Solutions Players by Revenue
- 6.1.1 Global Top Cell and Gene Therapy Enterprise Solutions Players by Revenue (2021-2026)
- 6.1.2 Global Cell and Gene Therapy Enterprise Solutions Revenue Market Share by Players (2021-2026)
- 6.2 Global Cell and Gene Therapy Enterprise Solutions Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Cell and Gene Therapy Enterprise Solutions Head Office and Area Served
- 6.4 Global Cell and Gene Therapy Enterprise Solutions Players, Product Type & Application
- 6.5 Global Cell and Gene Therapy Enterprise Solutions Manufacturers Established Date
- 6.6 Global Cell and Gene Therapy Enterprise Solutions Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032)
- 7.2 North America Cell and Gene Therapy Enterprise Solutions Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
- 7.4 North America Cell and Gene Therapy Enterprise Solutions Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032)
- 8.2 Europe Cell and Gene Therapy Enterprise Solutions Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
- 8.4 Europe Cell and Gene Therapy Enterprise Solutions Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032)
- 9.2 Asia-Pacific Cell and Gene Therapy Enterprise Solutions Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Cell and Gene Therapy Enterprise Solutions Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032)
- 10.2 South America Cell and Gene Therapy Enterprise Solutions Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
- 10.4 South America Cell and Gene Therapy Enterprise Solutions Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032)
- 11.2 Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Cell and Gene Therapy Enterprise Solutions Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Thermo Fisher Scientific
- 12.1.1 Thermo Fisher Scientific Company Information
- 12.1.2 Thermo Fisher Scientific Business Overview
- 12.1.3 Thermo Fisher Scientific Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.1.4 Thermo Fisher Scientific Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.1.5 Thermo Fisher Scientific Recent Developments
- 12.2 Miltenyi Biotec
- 12.2.1 Miltenyi Biotec Company Information
- 12.2.2 Miltenyi Biotec Business Overview
- 12.2.3 Miltenyi Biotec Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.2.4 Miltenyi Biotec Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.2.5 Miltenyi Biotec Recent Developments
- 12.3 Bruker Spatial Biology
- 12.3.1 Bruker Spatial Biology Company Information
- 12.3.2 Bruker Spatial Biology Business Overview
- 12.3.3 Bruker Spatial Biology Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.3.4 Bruker Spatial Biology Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.3.5 Bruker Spatial Biology Recent Developments
- 12.4 Charles River Laboratories
- 12.4.1 Charles River Laboratories Company Information
- 12.4.2 Charles River Laboratories Business Overview
- 12.4.3 Charles River Laboratories Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.4.4 Charles River Laboratories Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.4.5 Charles River Laboratories Recent Developments
- 12.5 Sartorius
- 12.5.1 Sartorius Company Information
- 12.5.2 Sartorius Business Overview
- 12.5.3 Sartorius Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.5.4 Sartorius Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.5.5 Sartorius Recent Developments
- 12.6 Revvity
- 12.6.1 Revvity Company Information
- 12.6.2 Revvity Business Overview
- 12.6.3 Revvity Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.6.4 Revvity Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.6.5 Revvity Recent Developments
- 12.7 Red Cross Blood Services
- 12.7.1 Red Cross Blood Services Company Information
- 12.7.2 Red Cross Blood Services Business Overview
- 12.7.3 Red Cross Blood Services Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.7.4 Red Cross Blood Services Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.7.5 Red Cross Blood Services Recent Developments
- 12.8 Proteintech Group
- 12.8.1 Proteintech Group Company Information
- 12.8.2 Proteintech Group Business Overview
- 12.8.3 Proteintech Group Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.8.4 Proteintech Group Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.8.5 Proteintech Group Recent Developments
- 12.9 Promega Corporation
- 12.9.1 Promega Corporation Company Information
- 12.9.2 Promega Corporation Business Overview
- 12.9.3 Promega Corporation Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.9.4 Promega Corporation Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.9.5 Promega Corporation Recent Developments
- 12.10 BIOMÉRIEUX
- 12.10.1 BIOMÉRIEUX Company Information
- 12.10.2 BIOMÉRIEUX Business Overview
- 12.10.3 BIOMÉRIEUX Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.10.4 BIOMÉRIEUX Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.10.5 BIOMÉRIEUX Recent Developments
- 12.11 QIAGEN
- 12.11.1 QIAGEN Company Information
- 12.11.2 QIAGEN Business Overview
- 12.11.3 QIAGEN Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.11.4 QIAGEN Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.11.5 QIAGEN Recent Developments
- 12.12 R&D Systems
- 12.12.1 R&D Systems Company Information
- 12.12.2 R&D Systems Business Overview
- 12.12.3 R&D Systems Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.12.4 R&D Systems Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.12.5 R&D Systems Recent Developments
- 12.13 Abcam
- 12.13.1 Abcam Company Information
- 12.13.2 Abcam Business Overview
- 12.13.3 Abcam Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.13.4 Abcam Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.13.5 Abcam Recent Developments
- 12.14 SGS
- 12.14.1 SGS Company Information
- 12.14.2 SGS Business Overview
- 12.14.3 SGS Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.14.4 SGS Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.14.5 SGS Recent Developments
- 12.15 Azenta US
- 12.15.1 Azenta US Company Information
- 12.15.2 Azenta US Business Overview
- 12.15.3 Azenta US Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.15.4 Azenta US Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.15.5 Azenta US Recent Developments
- 12.16 Vizient Inc
- 12.16.1 Vizient Inc Company Information
- 12.16.2 Vizient Inc Business Overview
- 12.16.3 Vizient Inc Revenue in Cell and Gene Therapy Enterprise Solutions Business (2021-2026)
- 12.16.4 Vizient Inc Cell and Gene Therapy Enterprise Solutions Product Portfolio
- 12.16.5 Vizient Inc Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst